Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. grew its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 27.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 259,429 shares of the medical equipment provider's stock after acquiring an additional 56,342 shares during the quarter. Raymond James Financial Inc. owned about 0.06% of Smith & Nephew SNATS worth $7,360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hexagon Capital Partners LLC lifted its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after buying an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. lifted its position in Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after buying an additional 1,000 shares in the last quarter. Bessemer Group Inc. lifted its position in Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares in the last quarter. Hara Capital LLC lifted its position in Smith & Nephew SNATS by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Finally, Opal Wealth Advisors LLC purchased a new position in Smith & Nephew SNATS during the first quarter worth approximately $73,000. Hedge funds and other institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Trading Up 1.2%

NYSE:SNN traded up $0.45 on Friday, reaching $38.09. The company's stock had a trading volume of 1,215,377 shares, compared to its average volume of 589,653. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $38.41. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 1.04 and a beta of 0.71. The stock has a 50 day moving average price of $33.57 and a 200 day moving average price of $30.04.

Smith & Nephew SNATS Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's payout ratio is presently 41.20%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SNN. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Canaccord Genuity Group lifted their target price on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research report on Monday, August 18th. Six investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $36.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.